6533b871fe1ef96bd12d2687

RESEARCH PRODUCT

Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome

Vedat TiyeriliGeorg NickenigBeat LutzJ JehleHanna GoerichLaura Bindila

subject

0301 basic medicineMalePhysiologyMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyVascular MedicineBiochemistryCoronary artery disease0302 clinical medicineMedicine and Health SciencesMedicineCoronary Heart DiseaseMyocardial infarctionNon-ST Elevated Myocardial InfarctionCoronary ArteriesAortaAged 80 and overMultidisciplinaryArachidonic AcidQREukaryotaNeurochemistryVenous bloodArteriesPlantsMiddle AgedLegumesLipidsCoronary VesselsBody Fluidsmedicine.anatomical_structureBloodCirculatory systemCardiologyMedicineArterial bloodEngineering and TechnologyFemaleAnatomyNeurochemicalsResearch ArticleBiotechnologyAcute coronary syndromemedicine.medical_specialtyCathetersScienceCardiologyBioengineeringArachidonic AcidsGlyceridesDiagnosis Differential03 medical and health sciencesCoronary circulationInternal medicineCoronary CirculationHumansAcute Coronary SyndromeAgedbusiness.industryMacrophagesOrganismsPeasBiology and Life Sciencesmedicine.diseaseCoronary arteries030104 developmental biologyCross-Sectional StudiesCardiovascular AnatomyBlood VesselsMedical Devices and EquipmentEndothelium VascularbusinessEndocannabinoidsNeuroscience

description

Objectives The endocannabinoid system modulates coronary circulatory function and atherogenesis. The two major endocannabinoids (eCB), 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (AEA), are increased in venous blood from patients with coronary artery disease (CAD). However, given their short half-life and their autocrine/paracrine mechanism of action, eCB levels in venous blood samples might not reflect arterial or coronary eCB concentrations. The aim of this cross-sectional study was to identify the local concentration profile of eCB and to detect whether and how this concentration profile changes in CAD and NSTEMI versus patients without CAD. Methods and results 83 patients undergoing coronary angiography were included in this study. Patients were divided into three groups based on their definite diagnosis of a) no CAD, b) stable CAD, or c) non-ST-segment elevation myocardial infarction (NSTEMI). Blood was drawn from the arterial sheath and the aorta in all patients and additionally distal to the culprit coronary lesion in CAD- and NSTEMI patients. 2-AG levels varied significantly between patient groups and between the sites of blood extraction. The lowest levels were detected in patients without CAD; the highest 2-AG concentrations were detected in NSTEMI patients and in the coronary arteries. Peripheral 2-AG levels were significantly higher in NSTEMI patients (107.4 ± 28.4 pmol/ml) than in CAD- (17.4 ± 5.4 pmol/ml; p < 0.001), or no-CAD patients (23.9 ± 7.1 pmol/ml; p < 0.001). Moreover, coronary 2-AG levels were significantly higher in NSTEMI patients than in CAD patients (369.3 ± 57.2 pmol/ml vs. 240.1 ± 25.3 pmol/ml; p = 0.024). Conclusions 2-AG showed significant variability in arterial blood samples drawn from distinct locations. Possibly, lesional macrophages synthesise 2-AG locally, which thereby contributes to endothelial dysfunction and local inflammation.

10.1371/journal.pone.0227142http://europepmc.org/articles/PMC6936850